아이큐어

175250KOSDAQ

53.4 / 100

Reference Date: 2026-09-08

Financial Score16.5 / 40

News Sentiment16.9 / 25

Momentum5.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 11.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

IQure, established in 2000, specializes in developing transdermal drug delivery systems (TDDS) and pharmaceutical patches, along with OEM/ODM cosmetics. Following the successful Phase III trial of its donepezil patch in 2021, the company has secured global licensing agreements with pharmaceutical giants like Menarini and Celltrion. It also operates an ISO-certified cosmetics manufacturing facility, focusing on skincare OEM/ODM.

Number of Employees

286people

Average Salary

10.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.95Industry Average 1.200.0Point

2.5x industry avg (risky)

ROE

-82.73Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

30.72Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲21.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲27.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.8% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Neutral
대상펫라이프 닥터뉴토, '마이펫페어' 참가…제품 최대 68% 할인
대상펫라이프의 닥터뉴토 부스 참가 소식으로 관련 반려동물 제품 시장 관심 증가.
Positive
아이큐어, 2분기 전년 동기 대비 흑자전환…매출 77%↑
아이큐어의 2분기 매출이 전년 동기 대비 77% 증가하며 흑자 전환을 달성했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,920Won52-week high 2,17052-week low 1,920

1-month return1.0Point

1m -11.52% (falling)

Volume trend3.0Point

Volume dry-up

Detailed Disclosure

22 totalPositive 8Neutral 14Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-04
Positive최대주주변경을수반하는주식담보제공계약체결2026-09-04
Neutral주식등의대량보유상황보고서(일반)2026-09-04
Neutral기타경영사항(자율공시) (최대주주 보유주식의 자발적 의무보유 시행)2026-09-03
Positive[기재정정]증권발행결과(자율공시) (제3자배정유상증자)2026-09-03